Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.50 |
| ▸ | CNR2 | P34972 | 7/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17837679 | 0.98 | PARP1 (0.49) | PARP1CNR2PARP2SYKHRH4 | |
| SCHEMBL3925158 | 0.88 | CNR2 (0.50) | CNR2SYKDGAT1MAP4K4 | |
| SCHEMBL410932 | 0.82 | CNR2 (0.49) | PARP1CNR2 | |
| SCHEMBL13490452 | 0.82 | CNR2 (0.42) | PARP1CNR2 | |
| SCHEMBL28801510 | 0.79 | CYP1A2 (0.59) | CNR2 | |
| SCHEMBL4299114 | 0.79 | CNR2 (0.46) | PARP1CNR2 | |
| Hydrochloric Acid SCHEMBL443946 | 0.78 | CYP1A2 (0.57) | CNR2 | |
| SCHEMBL8965901 | 0.78 | PRKCQ (0.61) | PARP1 | |
| SCHEMBL17844419 | 0.77 | CNR2 (0.48) | PARP1CNR2DGAT1MAP4K4 | |
| SCHEMBL24265537 | 0.76 | USP7 (0.45) | PARP1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233829-B1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER (US) | 2019-08-14 | — | — | EP | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| WO-2016097918-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176850-A1 | AXL INHIBITORS | AXL, FLT3, MERTK | PARP1 3144/4885CNR2 4422/4885PARP2 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.